DEXTROMETHORPHAN TO DEXTRORPHAN URINARY METABOLIC RATIO DOES NOT REFLECT DEXTROMETHORPHAN ORAL CLEARANCE
- 1 July 2005
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (7) , 1052-1055
- https://doi.org/10.1124/dmd.104.003459
Abstract
Dextromethorphan urinary metabolic ratio is widely used to determine the CYP2D6 phenotype, but its utility to reflect subtle differences in catalytic activity is unclear. We evaluated the capability of dextromethorphan urinary metabolic ratio to predict dextromethorphan oral clearance as a measure of CYP2D6 activity. Data from 10 healthy extensive metabolizers of CYP2D6 were given 30 mg of dextromethorphan hydrobromide orally on two occasions. Blood and urine samples were collected for 72 h. Dextromethorphan and dextrorphan were determined in urine by high-performance liquid chromatography with fluorescence detection and in serum by liquid chromatography-mass spectrometry. The urinary metabolic ratio was very weakly correlated with dextromethorphan oral clearance (r = 0.24; p = 0.04). In contrast, the dextromethorphan oral clearance was highly correlated with the dextromethorphan to dextrorphan area under the concentration-time curve ratio (r = 0.84; p = 0.005) and the 3-h (r = 0.60; p = 0.003), 4-h (r = 0.72, p < 0.001), 6-h (r = 0.67; p < 0.001), and 8-h (r = 0.74; p < 0.001) dextromethorphan to dextrorphan serum ratios. Assuming an effect size of 30%, the number of volunteers required for crossover and cross-sectional studies using the urinary metabolic ratio as the CYP2D6 index was calculated to be 56 and 524, respectively, whereas 14 and 60 subjects are needed if oral clearance is used. Considering the required sample size and the low correlation with oral clearance, urinary metabolic ratio is not recommended as the primary outcome variable in studies requiring the detection of modest changes in CYP2D6 activity.Keywords
This publication has 16 references indexed in Scilit:
- The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivoClinical Pharmacology & Therapeutics, 2004
- Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypesJournal of Biomedical Science, 2003
- CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medicationPharmacogenetics, 1997
- Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation*Clinical Pharmacology & Therapeutics, 1996
- The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans*Clinical Pharmacology & Therapeutics, 1996
- Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis*Clinical Pharmacology & Therapeutics, 1996
- Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activityJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Pharmacogenetics of dextromethorphan O-demethylation in manXenobiotica, 1986
- Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylationClinical Pharmacology & Therapeutics, 1985